Americas Gastrointestinal Drug Market 2018 Rise With Top Key Players; AbbVie Inc., AstraZeneca, Valeant, Abbott Laboratories, Allergan Plc

The Americas gastrointestinal drug market is expected to grow at CAGR of 5% during forecasted period 2018- 2023. The market will be growing in the coming future, as the sale of the OTC (over the counter) drugs for gastrointestinal diseases are more.

Americas Gastrointestinal (GI) drug market involves pharmacological and non-pharmacological treatment. Different types of gastrointestinal disorder includes constipation, diverticular diseases, colon polyps, irritable bowel syndrome, and many more. Many of the GI diseases can be prevented and minimized by maintaining a healthy lifestyle and balanced diet.

The factors like increasing prevalence of increasing of various different gastrointestinal disease, increasing elderly population, technological advances are responsible for driving gastrointestinal market. Whereas unavailability of treatment for some of gastro intestinal diseases may be responsible for hampering the market growth.

Get Sample PDF Illustration @ https://www.marketresearchfuture.com/sample_request/583 .

Key Players for Americas Gastrointestinal Drug Market

There are players in Americas Gastrointestinal Drug Market: AbbVie Inc. (US), AstraZeneca (UK), Valeant (US), Abbott Laboratories(US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals (US), Sanofi (France), GlaxoSmithKline Plc. (UK), Boehringer Ingelheim GmbH (Germany). Evoke Pharma (US), Valent Pharmaceuticals(US)

AstraZeneca has entered into an agreement with gastroenterology specialist Tillotts Pharma for Entocort. Entocort is a gastroenterology medicine for patients with mild to moderate Crohn’s disease and ulcerative colitis. The medicine is now available in across 40 countries, the product sales gained $53 million outside the US in 2014. The agreement shows that Tillotts will pay AstraZeneca $215 million on completion of the transaction to acquire the rights to sell and develop Entocort capsules and formulations outside the US.

Janssen Biotech Inc., the company received FDA approval for the Remicade medicine which is used to treat pediatric ulcerative colitis in 2011. Since then company has a product for pediatric gasrtrointestinal drugs.

GlaxoSmithKline Plc, has a products Eno available in Latin America and Asian market. The product is doing extremely well in these regions. The product is available in various flavor. The product is an antacid. The product is also available in different forms. Company has vast range of products in consumers based and in prescription based products. It hold very strong presence worldwide.

Bayer AG, the company has a wide range of the gastrointestinal products. One of the product Iberogast is herbal product which give relief from multiple problems of gastrointestinal system.

Segments for Americas Gastrointestinal Drug Market

The Segmentation for Americas Gastrointestinal Drug Market is done on the basis of drug category, route of administration, disease type, and by end users. On the basis of the drug category the market is segmented into Acid Neutralizers, Laxatives & Antidiarrheal, Anti-inflammatory, Antiemetic and others. Further the Acid Neutralizers are sub-segmented into Antacid, H2 antagonists, Proton Pump Inhibitors and others. On the basis of route of administration the segments includes oral, parental and rectal. On the basis of disease type, market is segmented into gastro-esophageal reflux diseases, inflammatory bowel diseases and others. The inflammatory diseases are further segmented into two types Crohn’s diseases and ulcerative disease. The Ulcerative diseases are further sub segmented into ulcerative protitis, proctosigmoiditis, left sided colitis, pancolitis and acute severe ulcerartive colitis. The end user segment includes hospital pharmacies, retail pharmacies and others.

Regional Analysis for Americas Gastrointestinal Drug Market

On regional basis America Gastrointestinal Drug Market is segmented into two main region- North America, and South America. North America has the highest market for the Gastrointestinal Drug Market. Increasing Geriatric Population is the major driving factor for the market of GI drugs in North America. While the major cause of the gastrointestinal diseases is stress full life and eating habit.

Get Prime Discount on Report @ https://www.marketresearchfuture.com/check-discount/583 .

Some Brief Table of Contents of Report

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

TOC Continued…

Do You Have Specific Requirement? Ask To Our Experts@ https://www.marketresearchfuture.com/enquiry/583 .

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Hadapsar, Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.